Company intelligence / Profile preview

LDS Development Corporation

Columbus, Ohio, United States

Ownership: Private
Development stage: Other

Overview

LDS Development Corporation is a clinical-stage biotechnology company focused on the development of novel lipid-based drug delivery technologies. The company utilizes its proprietary Lipid Delivery System (LDS) platform to create improved formulations of existing drugs, particularly those with poor solubility or high toxicity. Its lead candidate, LDS-paclitaxel, is a liposomal formulation of the widely used chemotherapy agent, aimed at treating various solid tumors with an enhanced safety profile. Beyond oncology, the company explores the application of its lipid technologies for the delivery of anti-infectives and nucleic acid-based therapeutics.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Small moleculeLipid nanoparticle delivery therapyNanoparticle
Industry: Biotech

Beyond the preview

Go deeper on LDS Development Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LDS Development Corporation.

Explore the full profile